Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of VED-002 for the treatment of Non-small cell lung cancer

Next Previous
X
Search
Trial Profile

Phase I/II trial of VED-002 for the treatment of Non-small cell lung cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 Mar 2022 According to an Elicio Therapeutics media release, plans to initiate this trial early next year.
    • 05 Feb 2021 According to an Elicio Therapeutics media release, ELI-002, targeting KRAS-driven cancers will begin initial patient studies in solid tumor patients in the first half of 2021.
    • 04 Oct 2019 According to an Elicio Therapeutics media release, six months after raising a $30 million series A round, company has added $33 million via its B round to begin Phase I/II testing of ELI-002.The series B, led by new investor Livzon Pharmaceutical Group.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top